The Challenge
An emerging diagnostics company developing an innovative, AI-enabled diagnostic test needed to establish a clinical validation strategy that would support both FDA regulatory requirements and future clinical adoption and reimbursement.
The challenge was to develop an evidence-generation plan that addressed regulatory expectations while also demonstrating clinical utility and value to healthcare providers and payers, avoiding the need for duplicative studies after-market authorization.
FHA's Approach
Frank Healthcare Advisors (FHA) worked closely with the company to develop an integrated regulatory, reimbursement, and clinical evidence strategy aligned with its long-term commercialization objectives.
FHA supported early engagement with FDA and key clinical and payer stakeholders to clarify the regulatory pathway, identify key evidentiary requirements, and establish expectations for clinical performance and utility.
Importantly, the strategy extended beyond regulatory submission requirements to consider the evidence needed to support physician confidence, integration into clinical workflows, payer coverage decisions, and reimbursement.
The Results
- A clearly defined regulatory pathway with a structured approach to FDA engagement.
- A comprehensive clinical validation strategy designed to support a future FDA premarket submission.
- Alignment of regulatory and commercial evidence needs, incorporating considerations for clinical adoption, payer coverage, and reimbursement.
- An efficient evidence-generation roadmap intended to maximize the value of clinical studies and minimize duplicative development efforts.
The FHA Advantage
This case demonstrates the value of developing a clinical evidence strategy that extends beyond regulatory authorization. By integrating FDA requirements with clinical and market access considerations early in development, FHA helped establish a robust, forward-looking clinical strategy designed to support regulatory success, clinical adoption, and reimbursement.
FHA helps medical technology companies generate the right evidence—not only to achieve regulatory authorization, but also to support successful commercialization.